Spots Global Cancer Trial Database for recurrent
Every month we try and update this database with for recurrent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy | NCT00604526 | Prostate Cancer | High dose rate ... | 18 Years - 85 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma | NCT02623127 | Thymic Carcinom... | Sunitinib | 20 Years - | Seoul National University Hospital | |
| Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT) | NCT05634707 | Primary Brain T... Brain Tumor, Re... | Fluoxetine Temozolomide | 24 Years - | Duke University | |
| Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC | NCT00378404 | Non-Small Cell ... | Docetaxel Radiation | 18 Years - | University of Kentucky | |
| Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma | NCT01583543 | Ewing's Sarcoma | Olaparib | 18 Years - | Massachusetts General Hospital | |
| A Panobinostat Presurgery | NCT01115036 | Recurrent Gliob... | panobinostat | 18 Years - | Duke University | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00484666 | Ovarian Cancer | 18 Years - | Carilion Clinic | ||
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection | NCT00816075 | Recurrent Super... Distilled Water | distilled water | - | Bozyaka Training and Research Hospital | |
| PRecISion Medicine for Children With Cancer | NCT03336931 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Molecular profi... | - 21 Years | Sydney Children's Hospitals Network | |
| A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR | NCT02687386 | Solid Tumours CNS Tumours | Mitoxantrone pa... | 2 Years - 21 Years | Sydney Children's Hospitals Network | |
| Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) | NCT01511081 | Non-small-cell ... | SBRT (stereotac... SBPT (stereotac... | 18 Years - | M.D. Anderson Cancer Center | |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | NCT01188876 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | carboplatin pralatrexate Folic Acid Vitamin B12 Inj... | 18 Years - | Massachusetts General Hospital | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection | NCT00816075 | Recurrent Super... Distilled Water | distilled water | - | Bozyaka Training and Research Hospital | |
| Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | NCT03557359 | Gliomas | Nivolumab | 18 Years - | Columbia University | |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | NCT02124707 | Head and Neck C... Squamous Cell C... | Cetuximab Paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | NCT04778956 | Nasopharyngeal ... PD-1 Surgery | Toripalimab salvage surgery | 18 Years - 70 Years | Sun Yat-sen University | |
| Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | NCT03795012 | Breast Cancer | Eribulin | 18 Years - | MedSIR | |
| RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes | NCT04266327 | Brachytherapy Squamous Cell C... | 3D-printing Tem... | 18 Years - 75 Years | Peking University Third Hospital | |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | NCT02288897 | Cutaneous Melan... | PV-10 (10% rose... Dacarbazine, te... | 18 Years - | Provectus Pharmaceuticals | |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | NCT01610206 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Gemcitabine pazopanib | 18 Years - | University of Virginia | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | NCT03690869 | Relapsed Solid ... Refractory Soli... Relapsed Centra... Refractory Cent... Diffuse Intrins... High Grade Glio... | cemiplimab (mon... cemiplimab (mai... Conventional or... Re-irradiation | - 25 Years | Regeneron Pharmaceuticals | |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder | NCT02202772 | Urothelial Carc... | Cabazitaxel Gemcitabine Cisplatin | 18 Years - | Columbia University | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | NCT00035061 | Urologic Neopla... Metastases, Neo... | pemetrexed | 18 Years - | Eli Lilly and Company | |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) | NCT00356122 | Non-Small Cell ... | Docetaxel Oxaliplatin Bevacizumab | 18 Years - | Sanofi | |
| Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | NCT04469075 | Glioblastoma Recurrent Gliob... Skin Toxicity | Clindamycin Pho... Triamcinolone A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | NCT03215810 | Non-Small Cell ... Metastatic Non-... Squamous Cell C... Advanced NSCLC Adenosquamous C... Adenocarcinomas | Tumor-infiltrat... Nivolumab Cyclophosphamid... Fludarabine Tumor-infiltrat... Interleukin-2 (... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| OSCA - Olaparib Standard of CAre Study | NCT02262273 | Platinum-sensit... | Data Collection | 18 Years - | AstraZeneca | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 | NCT04590326 | Ovarian Cancer Fallopian Tube ... Primary Periton... Endometrial Can... | REGN5668 Cemiplimab REGN4018 Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III | NCT02761070 | Glioblastoma Recurrence Progression | Temozolomide Bevacizumab | 20 Years - 75 Years | Kyorin University | |
| Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | NCT01531205 | Prostate Cancer | Androgen Ablati... Cabazitaxel Salvage Therapy Neoadjuvant Tre... Neoadjuvant Tre... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| AMG 102 and Avastin for Recurrent Malignant Glioma | NCT01113398 | Glioblastoma Mu... Gliosarcoma | AMG 102 Avastin | 18 Years - | Duke University | |
| A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma | NCT01562197 | Glioblastoma Mu... | axitinib Axitinib plus L... | 18 Years - 99 Years | Universitair Ziekenhuis Brussel | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | NCT00401635 | Endometrial Can... | liposomal doxor... carboplatin | 18 Years - 75 Years | National Cancer Institute, Naples | |
| Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | NCT03298074 | Ovarian Cancer | Apatinib Etoposide | 18 Years - | Guangxi Medical University | |
| Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma | NCT00545545 | Recurrent Color... Progressive Col... | Safety and effi... Safety and effi... | 18 Years - 75 Years | HiberCell, Inc. | |
| Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma | NCT02438501 | Recurrent Folli... | Low-dose involv... Involved-field ... | 18 Years - 65 Years | Wuhan University | |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III | NCT02761070 | Glioblastoma Recurrence Progression | Temozolomide Bevacizumab | 20 Years - 75 Years | Kyorin University | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | NCT01531205 | Prostate Cancer | Androgen Ablati... Cabazitaxel Salvage Therapy Neoadjuvant Tre... Neoadjuvant Tre... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | NCT00635557 | Glioblastoma Mu... | MPC-6827 + Carb... | 18 Years - | Myrexis Inc. | |
| Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | NCT05815160 | Small Cell Lung... | Debio 0123 Etoposide Carboplatin | 18 Years - | Debiopharm International SA | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) | NCT00356122 | Non-Small Cell ... | Docetaxel Oxaliplatin Bevacizumab | 18 Years - | Sanofi | |
| Topotecan Pharmacokinetic Characterization Study | NCT00361803 | Cancer | topotecan | 18 Years - | GlaxoSmithKline | |
| Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | NCT03666221 | Recurrent Nasop... | Nimotuzumab | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | NCT01623349 | Ovarian Cancer Breast Cancer | BKM120 and Olap... BYL719 and Olap... | 18 Years - | Dana-Farber Cancer Institute | |
| Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study | NCT02355054 | Cancer of the P... | C-11 Choline PE... | 18 Years - | Washington University School of Medicine | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Pediatric Longitudinal Cohort Study of Chronic Pancreatitis | NCT03672422 | Pancreatitis, C... Pancreatitis, A... | Blood sample Patient questio... Saliva sample Urine sample | 0 Years - 17 Years | University of Iowa | |
| Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer | NCT01458847 | Non-muscle Inva... | cis-UCA solutio... cis-UCA solutio... cis-UCA solutio... | 18 Years - 80 Years | BioCis Pharma Ltd | |
| Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck | NCT02624128 | Squamous Cell C... | Valproic Acid Cisplatin Cetuximab | 18 Years - | National Cancer Institute, Naples | |
| Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma | NCT00712062 | Primary Central... | Pemetrexed | 18 Years - | University of Florida | |
| A Study of ZEN003694 in People With Squamous Cell Lung Cancer | NCT05607108 | Squamous Cell L... | ZEN003694 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT01851408 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | NCT03970447 | Glioblastoma | Temozolomide Lomustine Regorafenib Radiation Paxalisib VAL-083 VT1021 Troriluzole ADI-PEG 20 | 18 Years - | Global Coalition for Adaptive Research | |
| Study of XL999 in Patients With Previously Treated Ovarian Cancer | NCT00277290 | Ovarian Cancer | XL999 | 18 Years - | Symphony Evolution, Inc. | |
| Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | NCT00729053 | Renal Cell Carc... | IMO-2055 | 18 Years - | Idera Pharmaceuticals, Inc. | |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | NCT05329545 | High Grade Sero... Fallopian Tube ... Primary Periton... | Upifitimab rils... Placebo | 18 Years - | Mersana Therapeutics | |
| Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases | NCT00362817 | Brain Tumor Brain Metastase... | carboplatin temozolomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Vinorelbine for Recurrent ALCL-2017 | NCT03443128 | Anaplastic Larg... Vinorelbine | Vinorelbine | - 18 Years | Children's Cancer Group, China | |
| A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung | NCT00752206 | Osteosarcoma | Saracatinib Placebo | 15 Years - 74 Years | Sarcoma Alliance for Research through Collaboration | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Study of Pemetrexed for Second-Line Pancreas Cancer | NCT00864513 | Pancreas Cancer | pemetrexed | 18 Years - | Georgetown University | |
| Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC | NCT00510107 | Stomach Neoplas... Stage IV Recurrent | oxaliplatin Cisplatin | 18 Years - 75 Years | Gachon University Gil Medical Center | |
| Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC | NCT01864772 | Metastatic or R... | Carbo, 5FU, Cet... | 70 Years - | Groupe Oncologie Radiotherapie Tete et Cou | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | NCT02932280 | Solid Tumor Central Nervous... Lymphoma Leukemia | Neratinib | 3 Years - 21 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | NCT02151084 | Biliary Tract C... Gallbladder Car... | Selumetinib Cisplatin Gemcitabine | 18 Years - | University Health Network, Toronto | |
| "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01883297 | Recurrent Platinum-resist... High Grade Sero... Fallopian Tube ... Primary Periton... | Re-stimulated t... Interleukin-2 Cyclophosphamid... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
